文章摘要
高迪,谢靖凡,韩娟娟,柴慧婷,顾金辉.我国药品强制许可制度存在的问题及对策[J].中华医学图书情报杂志,2017,26(6):36-40.
我国药品强制许可制度存在的问题及对策
Problems in China pharmaceutical compulsory licensing system and their solutions
投稿时间:2017-04-18  
DOI:10.3969/j.issn.1671-3982.2017.06.009
中文关键词: 专利法、强制许可、公共卫生健康
英文关键词: Patent law  Compulsory licensing  Public health
基金项目:
作者单位
高迪 中国医学科学院病原生物学研究所北京100730 
谢靖凡 厦门大学科技处福建 厦门361005 
韩娟娟 国家卫生和计划生育委员会北京100044 
柴慧婷 国家卫生和计划生育委员会北京100044 
顾金辉 国家卫生和计划生育委员会北京100044 
摘要点击次数: 760
全文下载次数: 352
中文摘要:
      面对全球公共健康的严峻形式,《多哈宣言》赋予WHO成员国处理公共健康危机时,具有使用药品专利强制许可的权利。虽然我国已基本建立药品专利强制许可制度,但是在实际工作中存在实施效力较低、行政主管部门职责不清、制药企业对有关规定了解不足等诸多问题,需要改进、完善有关法律规定和相关制度,切实提高药物可及性。
英文摘要:
      The Doha Declaration has entrusted to the members of WHO the right to use the compulsory licensing for drug patents in the face of global public health crises. Although the basic compulsory licensing system for drug patents has been established in China, the efficiency of its implementation is low, the responsibility of its executive departments is unclear, the related rules are not fully understood by pharmaceutical enterprises, it is thus necessary to improve and perfect the relevant legal provisions and systems in order to effectively improve the accessibility of drugs.
HTML    查看全文   查看/发表评论  下载PDF阅读器
手机扫一扫看